David Mott has served as Chairman of the Complexa Board of Directors since 2017. He currently serves as a General Partner for New Enterprise Associates (NEA) and leads the healthcare investing practice, which typically comprises roughly one-third of each fund, or $1.1 billion of healthcare venture investments every two-to-three years. Prior to joining NEA, David was President and Chief Executive Officer of MedImmune, a subsidiary of AstraZeneca Plc, and Executive Vice President of AstraZeneca. David joined MedImmune in 1992 and served in various leadership and senior management roles from 2000 to 2008, including President and Chief Executive Officer, Chief Financial Officer, and President and Chief Operating Officer. He led the sale of MedImmune to AstraZeneca in June 2007 for $15.6 billion. Prior to joining MedImmune, David was a Vice President in Health Care Investment Banking at Smith Barney, Harris Upham & Co., Inc. where he focused on public and private equity and debt financings as well as mergers and acquisitions. He received a BA in Economics and Government from Dartmouth College. In addition to Complexa, David is currently Chairman of 3-V Biosciences, Adaptimmune (NASDAQ: ADAP), Ardelyx (NASDAQ: ARDX), Cydan, Epizyme (NASDAQ: EPZM), Imara, Mersana (NASDAQ: MRSN), and TESARO (NASDAQ: TSRO), and is a director of Clementia, Nightstar and Xtuit.